A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 22,317 shares of EWTX stock, worth $507,711. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,317
Previous 38,000 41.27%
Holding current value
$507,711
Previous $498,000 27.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$12.61 - $16.59 $3.82 Million - $5.03 Million
-302,932 Reduced 93.14%
22,317 $361,000
Q2 2025

Aug 14, 2025

BUY
$11.42 - $20.13 $2.6 Million - $4.59 Million
227,971 Added 234.35%
325,249 $4.26 Million
Q1 2025

May 15, 2025

SELL
$22.0 - $30.03 $8.19 Million - $11.2 Million
-372,173 Reduced 79.28%
97,278 $2.14 Million
Q4 2024

Feb 14, 2025

SELL
$26.63 - $36.62 $1.83 Million - $2.52 Million
-68,798 Reduced 12.78%
469,451 $12.5 Million
Q3 2024

Nov 14, 2024

SELL
$15.88 - $29.5 $28.8 Million - $53.4 Million
-1,810,925 Reduced 77.09%
538,249 $14.4 Million
Q2 2024

Aug 14, 2024

SELL
$15.08 - $21.23 $5.58 Million - $7.86 Million
-370,117 Reduced 13.61%
2,349,174 $42.3 Million
Q1 2024

May 15, 2024

BUY
$9.25 - $19.97 $1.23 Million - $2.66 Million
133,361 Added 5.16%
2,719,291 $49.6 Million
Q4 2023

Feb 14, 2024

SELL
$5.51 - $12.1 $1 Million - $2.2 Million
-181,506 Reduced 6.56%
2,585,930 $28.3 Million
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $529,715 - $710,909
92,446 Added 3.46%
2,767,436 $15.9 Million
Q2 2023

Aug 14, 2023

SELL
$5.71 - $10.29 $533,588 - $961,579
-93,448 Reduced 3.38%
2,674,990 $20.7 Million
Q1 2023

May 15, 2023

SELL
$6.66 - $11.33 $520,019 - $884,657
-78,081 Reduced 2.74%
2,768,438 $18.5 Million
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $642,746 - $939,528
84,795 Added 3.07%
2,846,519 $25.4 Million
Q3 2022

Nov 14, 2022

BUY
$8.08 - $13.58 $1.81 Million - $3.04 Million
223,706 Added 8.81%
2,761,724 $27.2 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.44B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.